LX31 Stock Chart & Stats
€1.01
€0.00(0.00%)
At close: 4:00 PM EDT
€1.01
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€0.88 - €1.45
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€889.74M
Enterprise Value€511.43
Total Cash (Recent Filing)€170.66M
Total Debt (Recent Filing)€57.71M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 06, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.07
Shares Outstanding444,196,380
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.88
Price to Sales (P/S)8.38
P/FCF Ratio-6.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€4.36Price Target Upside332.12% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€32.88M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Collaboration MonetizationThe company has demonstrated an ability to convert partnership progress into cash via milestone recognition, shown by the step-up in revenue. This monetization capability is a durable commercial lever: it funds R&D and operations, validates external partner interest, and reduces near-term financing urgency over the next several quarters.
Exceptional Gross Margins On Recognized RevenueVery high gross margins indicate that recognized revenue (milestones, royalties, limited product sales) is highly accretive and leaves greater room to cover fixed operating costs. Over the medium term this supports leverage of limited revenues into meaningful operating improvements if revenue streams continue or scale through partnerships.
Improved Liquidity And Capital StructureA materially stronger cash balance, modestly reduced debt, and a committed term facility extend runway and reduce immediate refinancing pressure. This structural liquidity improvement gives management flexibility to fund clinical execution, seek partners, or advance programs without urgent dilutive financing over the next 2–6 months.
Bears Say
Persistent Negative Operating And Free Cash FlowContinued negative operating and free cash flow represents a structural cash consumption trend. If milestone timing slips or partner payments are delayed, the company will need additional funding; sustained negative cash flow can erode liquidity and force dilutive financings or program cutbacks within a medium-term horizon.
Revenue Heavily Milestone-dependentReliance on partner-triggered milestone payments makes revenue unpredictable and nonrecurring. Without scaled organic commercialization, cash generation and forecasting hinge on third-party development and regulatory events, increasing volatility and financing uncertainty over the coming quarters.
Dependence On Partners And Conditional Financing TranchesLate‑stage program progress and access to additional debt capital depend on external counterparties and achievement of clinical/regulatory milestones. This limits Lexicon's control over funding and timing, raising execution risk for Phase III and commercialization planning if partners or tranche conditions are not met.
Lexicon Pharmaceuticals News
LX31 FAQ
What was Lexicon Pharmaceuticals’s price range in the past 12 months?
Lexicon Pharmaceuticals lowest stock price was €0.88 and its highest was €1.45 in the past 12 months.
What is Lexicon Pharmaceuticals’s market cap?
Lexicon Pharmaceuticals’s market cap is €889.74M.
When is Lexicon Pharmaceuticals’s upcoming earnings report date?
Lexicon Pharmaceuticals’s upcoming earnings report date is Aug 06, 2026 which is in 2 days.
How were Lexicon Pharmaceuticals’s earnings last quarter?
Lexicon Pharmaceuticals released its earnings results on May 07, 2026. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.029 by €0.029.
Is Lexicon Pharmaceuticals overvalued?
According to Wall Street analysts Lexicon Pharmaceuticals’s price is currently Undervalued.
Does Lexicon Pharmaceuticals pay dividends?
Lexicon Pharmaceuticals does not currently pay dividends.
What is Lexicon Pharmaceuticals’s EPS estimate?
Lexicon Pharmaceuticals’s EPS estimate is -0.04.
How many shares outstanding does Lexicon Pharmaceuticals have?
Lexicon Pharmaceuticals has 444,196,380 shares outstanding.
What happened to Lexicon Pharmaceuticals’s price movement after its last earnings report?
Lexicon Pharmaceuticals reported an EPS of €0 in its last earnings report, beating expectations of -€0.029. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Lexicon Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:LX31
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexicon Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€4.36 (332.12% Upside)
€4.36 (332.12% Upside)
Blogger Sentiment
Bullish
DE:LX31 Sentiment 67%
Sector Average 65%
Sector Average 65%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.65%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-9.69%
Trailing 12-Months
Company Description
Lexicon Pharmaceuticals
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the end-to-end process of identifying, advancing, and bringing to market novel therapeutic compounds. Its development pipeline includes orally administered small molecule drug candidates such as Sotagliflozin, which has successfully concluded Phase III clinical studies for treating both heart failure and type 1 diabetes, and LX9211, currently undergoing Phase II clinical development for neuropathic pain. The firm maintains important strategic collaborations and licensing arrangements with pharmaceutical industry leaders, including Bristol-Myers Squibb Company and Genentech, Inc. Established in 1995, Lexicon Pharmaceuticals, Inc. is based in The Woodlands, Texas.
LX31 Company Deck
LX31 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized substantial progress across multiple fronts: large milestone-driven revenue, meaningful improvements in net loss, a stronger liquidity position, and clear clinical development milestones (SONATA enrollment completion mid-2026; Zynquista NDA resubmission midyear; LX9851 in Phase I; pilavapadin Phase III readiness). At the same time, several risks remain: the revenue uplift was largely one-time milestone-driven with limited organic sales, continued dependence on partners and conditional debt tranches, regulatory and enrollment uncertainties, and competitive dynamics in HCM. On balance, the highlights — particularly financial strengthening and late-stage program momentum — outweigh the lowlights, though execution risk into the second half of 2026 remains important.View all DE:LX31 earnings summariesLX31 Stock 12 Month Forecast
Average Price Target
€4.36
▲(332.12% Upside)